dc.contributor.author
Xu, Wenhao
dc.contributor.author
Li, Haoming
dc.contributor.author
Hameed, Yasir
dc.contributor.author
Abdel-Maksoud, Mostafa A.
dc.contributor.author
Almutairi, Saeedah Musaed
dc.contributor.author
Mubarak, Ayman
dc.contributor.author
Aufy, Mohammed
dc.contributor.author
Alturaiki, Wael
dc.contributor.author
Alshalani, Abdulaziz J.
dc.contributor.author
Li, Chen
dc.date.accessioned
2023-10-19T06:35:01Z
dc.date.available
2023-10-19T06:35:01Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/41186
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40907
dc.description.abstract
N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern in specific malignancies. We found two independent patterns of m6A alteration in ACC patients. The TME cell infiltration features were significantly in accordance with phenotypes of tumor immune-inflamed and immune desert in both patterns. The m6Ascore also served as an independent predictive factor in ACC patients. The somatic copy number variation (CNV) and patients prognosis can be predicted by m6A alteration patterns. Moreover, the ACC patients with high m6A scores had better overall survival (OS) and higher efficiency in immune checkpoint blockade therapy. Our work demonstrated the significance of m6A alteration to the ACC patients immunotherapy. The individual m6A alteration patterns analysis might contribute to ACC patients prognosis prediction and immunotherapy choice.
en
dc.format.extent
13 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Tumor microenvironment
en
dc.subject
Adrenocortical carcinoma
en
dc.subject
Immunotherapy
en
dc.subject.ddc
500 Naturwissenschaften und Mathematik::570 Biowissenschaften; Biologie::570 Biowissenschaften; Biologie
dc.title
Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.32604/or.2023.029414
dcterms.bibliographicCitation.journaltitle
Oncology Research
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.pagestart
819
dcterms.bibliographicCitation.pageend
831
dcterms.bibliographicCitation.volume
31
dcterms.bibliographicCitation.url
https://doi.org/10.32604/or.2023.029414
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Chemie und Biochemie
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1555-3906
refubium.resourceType.provider
WoS-Alert